Cargando…

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis

BACKGROUND: The association between the expression of programmed cell death-ligand 1 (PD-L1) and survival in patients with non-small-cell lung cancer (NSCLC) is controversial. Thus, we conducted a meta-analysis of all available studies to evaluate the prognostic role of PD-L1 expression in NSCLC. MA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Anyuan, Xing, Yufei, Pan, Xue, Shi, Minhua, Xu, Huajun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671817/ https://www.ncbi.nlm.nih.gov/pubmed/26664143 http://dx.doi.org/10.2147/OTT.S91469

Ejemplares similares

The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis
por: Zhong, Anyuan, et al.
Publicado: (2015)

FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer
por: Zhong, Anyuan, et al.
Publicado: (2021)

An Updated Meta-Analysis of the Association between Tumor Necrosis Factor-α -308G/A Polymorphism and Obstructive Sleep Apnea-Hypopnea Syndrome
por: Zhong, Anyuan, et al.
Publicado: (2014)

−148 C/T polymorphism of Axin2 contributes to a decreased risk of cancer: evidence from a meta-analysis
por: Zhong, AnYuan, et al.
Publicado: (2015)

Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
por: Piao, Jinlan, et al.
Publicado: (2020)

A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report
por: Pan, Xue, et al.
Publicado: (2021)

Expression of PD-1 by CD4(+)CD25(+)CD127(low) Treg cells in the peripheral blood of lung cancer patients
por: Zhong, AnYuan, et al.
Publicado: (2015)

Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
por: Cai, Huarong, et al.
Publicado: (2020)

Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
por: Wang, Shuo, et al.
Publicado: (2021)

The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
por: Xiao, Wen-jun, et al.
Publicado: (2019)

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
por: Miglietta, Federica, et al.
Publicado: (2019)

Correction to: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021)

Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis
por: Zhang, Yingzi, et al.
Publicado: (2020)

Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis
por: Guo, Yawen, et al.
Publicado: (2016)

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
por: Zhu, Zhenhua, et al.
Publicado: (2017)

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
por: Zhu, Jun, et al.
Publicado: (2017)

The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis
por: Zhao, Shu, et al.
Publicado: (2018)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
por: Niedźwiedzka-Rystwej, Paulina, et al.
Publicado: (2022)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

Nomogram for predicting 90-day mortality in patients with Acinetobacter baumannii-caused hospital-acquired and ventilator-associated pneumonia in the respiratory intensive care unit
por: Pei, Yongjian, et al.
Publicado: (2023)

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
por: Li, Xiao-Song, et al.
Publicado: (2020)

Comparison of the Prognostic Value of Ki-67 and Programmed Cell Death Ligand-1 in Patients with Upper Tract Urothelial Carcinoma
por: Tsai, Mu-Yao, et al.
Publicado: (2021)

Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer
por: Koganemaru, Shigehiro, et al.
Publicado: (2017)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma
por: Zhong, Anyuan, et al.
Publicado: (2021)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

POLRMT over‐expression is linked to WNT/beta‐catenin signaling, immune infiltration, and unfavorable outcomes in lung adenocarcinoma patients
por: Huang, Yongkang, et al.
Publicado: (2023)

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients
por: Liu, Xiaofeng, et al.
Publicado: (2019)

Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis
por: Huang, Xin, et al.
Publicado: (2018)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Prognostic value of programmed cell death ligand-1 expression in the tumor-infiltrating immune cells of patients with lung cancer: A meta-analysis
por: Berele, Birhanu Aberha, et al.
Publicado: (2021)

Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer
por: Kim, Seok-Hyun, et al.
Publicado: (2019)

Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis
por: Li, Ji, et al.
Publicado: (2017)

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
por: Mino-Kenudson, Mari
Publicado: (2016)

Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer
por: Kim, Hyojin, et al.
Publicado: (2018)

Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis
por: Şahin, Songül, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_je1kvojrnssbfqvmct4afq6j2t